Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...

AI can’t be fully trusted, yet businesses depend on it. Explore the risks of bias, hallucinations, and adversarial ...

Holding signs and banners reading Stop the AI Race and Don’t Build Skynet, the protesters marched through the city and gave ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals, Inc. before investing. In this article, we go over a ...

President Trump this week complained that America’s allies hadn’t stepped up to help break the Iranian blockade of the Strait of Hormuz. “Some are very enthusiastic about it, and some aren’t,” he said ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...